What is your approach for endocrine therapy in young women (<35 years old) with HR+/HER2+ breast CA with residual disease after TCHP who will start adjuvant T-DM1?

Answer from: Medical Oncologist at Academic Institution

She would be given the options of tamoxifen or ovarian suppression with an AI for five years and then a discussion at that time based on where the data goes in that time. Tamoxifen would have fewer side effects but less effective reduction of PFS per extrapolation from the SOFT/TEXT trials. Ovarian ...

Comments

Medical Oncologist at Northwestern Medicine Cancer Center at KishHealth
Would you start anti estrogen therapy concurrently...

Medical Oncologist at Cedars-Sinai Medical Center
I agree that I would give OFS plus an AI in this h...

Medical Oncologist at Boston University School of Medicine
Neratinib (for 12 months) is also approved after c...

Medical Oncologist at Los Angeles VA Medical Center
The question of concurrent anti-endocrine therapy ...

Medical Oncologist at NYU Winthrop Hospital
The SOFT/TEXT trial was done in ER positive tumors...

Medical Oncologist at UT MD Anderson Cancer Center
Actually, 14% of patients had HER2 positive diseas...

Answer from: Medical Oncologist at Community Practice

In these higher risk patients, I extrapolate from SOFT/TEXT and offer OS/AI.

Answer from: Medical Oncologist at Community Practice

The patient is at high risk. I would recommend ovarian suppression (SOFT and TEXT approach) along with anti-Her2 therapy.

Comments

Medical Oncologist at St Lukes Cancer Care Assocs
I would give ET (OS+AI) with Anti-HER-2. I would g...

Please select the option that best describes you:

What is your approach for endocrine therapy in young women (<35 years old) with HR+/HER2+ breast CA with residual disease after TCHP who will start adjuvant T-DM1?

Related Questions